News

Catabasis to Present DMD Candidate Treatment at International Congress of the World Muscle Society

CAT-1004, a candidate treatment for Duchenne muscular dystrophy (DMD) being developed by Catabasis Pharmaceuticals, will be featured in a poster presentation at the International Congress of the World Muscle Society, taking place in Berlin, Germany between October 7 and 11. Catabasis Pharmaceuticals is a drug developer currently focused on the development of clinical…

Duke Blue Devils Supports the Fight Against Duchenne MD

Duchenne muscular dystrophy (DMD), a highly fatal hereditary disorder, affects one in every 3,600 young boys. It commonly begins with muscle weakness and loss in muscle mass. This muscle wasting is eventually replaced by fat and fibrotic tissue, eventually making it difficult to stand and walk, oftentimes by…

MD-CARE Act on Muscular Dystrophy Research Passes in the Senate

The MD-CARE Act, a piece of legislation designed to accelerate research and provide infrastructure needed for the development of new treatments to treat all nine forms of muscular dystrophy, has passed in the Senate by unanimous consent on September 18th. The Muscular Dystrophy Association (MDA), which has been a major advocate for passage of…